NCT05833282

Brief Summary

Multicenter retrospective study conducted in the intensive care units of Tourcoing, Roubaix, and Lille hospitals. Patients hospitalized in the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU will be selected from microbiology laboratory data. Patient demographics and clinical data will be collected from the medical record. Microbiological results will be collected from the laboratory data.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2022

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

April 4, 2023

Completed
23 days until next milestone

First Posted

Study publicly available on registry

April 27, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
Last Updated

April 27, 2023

Status Verified

April 1, 2023

Enrollment Period

12 months

First QC Date

April 4, 2023

Last Update Submit

April 26, 2023

Conditions

Drug Resistance, Multiple, Bacterial

Outcome Measures

Primary Outcomes (1)

  • The primary endpoint is all-cause 30-day mortality.

    all-cause mortality.

    30-day mortality

Secondary Outcomes (1)

  • Adequacy of initial antibiotic therapy to french recommendations

    adequate within 30 days

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients admitted to the ICU with EBLSE bacteremia

You may qualify if:

  • Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU.

You may not qualify if:

  • Patient who is a minor, protected adult, or who refuses to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier DRON

Tourcoing, 59208, France

RECRUITING

Central Study Contacts

MEYBECK Angès, MD

CONTACT

0320694238recherche@ch-tourcoing.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2023

First Posted

April 27, 2023

Study Start

July 1, 2022

Primary Completion

June 30, 2023

Study Completion

June 30, 2023

Last Updated

April 27, 2023

Record last verified: 2023-04

Locations

FR(1)